Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14437MR)

This product GTTS-WQ14437MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, RO4858696-000(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ14437MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2705MR IVTScrip™ mRNA-Anti-CD19&CD3E, AMG103(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG103
GTTS-WQ564MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 62-71-3
GTTS-WQ5433MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ7763MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ3761MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10625MR IVTScrip™ mRNA-Anti-MAPT, LY-3303560(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY-3303560
GTTS-WQ6919MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ14213MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA RG4934
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW